Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

15.7%

27 terminated/withdrawn out of 172 trials

Success Rate

80.1%

-6.4% vs industry average

Late-Stage Pipeline

33%

56 trials in Phase 3/4

Results Transparency

69%

75 of 109 completed trials have results

Key Signals

18 recruiting75 with results21 terminated6 withdrawn

Enrollment Performance

Analytics

Phase 2

57(34.8%)

Phase 3

47(28.7%)

Phase 1

46(28.0%)

Phase 4

9(5.5%)

Early Phase 1

3(1.8%)

N/A

2(1.2%)

164Total

Phase 2(57)

Phase 3(47)

Phase 1(46)

Phase 4(9)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (172)

Showing 20 of 172 trials

NCT06703073Phase 2Recruiting

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)

Role: lead

NCT06701682Phase 2Recruiting

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab

Role: lead

NCT07053800Phase 2Recruiting

Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)

Role: collaborator

NCT06701669Phase 2Recruiting

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart

Role: lead

NCT06701656Phase 2Recruiting

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab

Role: lead

NCT06134362Phase 3Active Not Recruiting

Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)

Role: collaborator

NCT04827979Phase 1Completed

Daratumumab and Belatacept for Desensitization

Role: collaborator

NCT03949855Phase 2Recruiting

Belimumab With Rituximab for Primary Membranous Nephropathy

Role: collaborator

NCT06594068Phase 4Recruiting

Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users

Role: collaborator

NCT05123703Phase 3Active Not Recruiting

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

Role: collaborator

NCT06422767Phase 1Completed

Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers

Role: collaborator

NCT07562087Phase 2Active Not Recruiting

A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure

Role: collaborator

NCT06795893Recruiting

The Anifrolumab PRIM Program

Role: collaborator

NCT05948540Phase 2Suspended

Department of Defense PTSD Adaptive Platform Trial - Intervention C - Daridorexant

Role: collaborator

NCT05422612Phase 2Suspended

Department of Defense PTSD Adaptive Platform Trial - Master Protocol

Role: collaborator

NCT07015996Phase 2Recruiting

Efficacy of Tezepelumab in Peanut Oral Immunotherapy

Role: collaborator

NCT06659029Recruiting

Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users

Role: collaborator

NCT05602025Phase 1Completed

A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult Participants

Role: collaborator

NCT05917509Phase 3Completed

A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy

Role: collaborator

NCT05948553Phase 2Suspended

Department of Defense PTSD Adaptive Platform Trial - Intervention A - Fluoxetine

Role: collaborator